The efficacy analysis of radioactive iodine therapy for familial non-medullary thyroid cancer in the era of personalized medicine: a cohort study and a meta-analysis
IF 2.5 4区 医学Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
{"title":"The efficacy analysis of radioactive iodine therapy for familial non-medullary thyroid cancer in the era of personalized medicine: a cohort study and a meta-analysis","authors":"Jingjia Cao, Xiang Li, Huazhen Liang, Yang Li, Fei Zhao, Aiqiang Dong","doi":"10.1007/s12149-025-02029-4","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Compared with those of sporadic differentiated thyroid cancer (SDTC), the tumor characteristics of familial nonmedullary thyroid cancer (FNMTC) remain debatable. In addition, there is a paucity of data suggesting that their response to radioactive iodine (RAI) therapy differs from that of SDTC. We aimed to determine whether FNMTC is a homogenous biological entity that differs from SDTC in RAI therapy.</p><h3>Methods</h3><p>We retrospectively analyzed patients who underwent adjuvant ablative iodine radiotherapy between July 2016 and March 2020. We compared the differences in clinicopathological features and prognoses between the FNMTC and SDTC groups. The endpoint of the study was the rate of therapeutic response after 1 and 3 years of follow-up after first-line treatment. The response to therapy was classified into four categories: excellent response (ER), biochemical incomplete response (BIR), structural incomplete response (SIR) and indeterminate response (IDR). In addition, we conducted a meta-analysis of cohort studies to investigate the clinical outcomes.</p><h3>Results</h3><p>Of all the patients (<i>n</i> = 1758), 109 (6.2%) were classified as having FNMTC, whereas the remaining 1649 (93.8%) had SDTC. A greater proportion of FNMTC patients presented with extrathyroidal extension, capsular invasion, and multifocality (<i>P</i> = 0.01). In addition, patients with FNMTC were more likely to have advanced primary tumor stage and lymph node metastasis, but the differences were not statistically significant. At the end of follow-up (median follow-up of 3 years), the response to RAI therapy was significantly different between the two groups (ER: 66.1% <i>vs</i> 74.3%; IDR: 9.2% <i>vs</i> 12.1%; SIR: 14.7% <i>vs</i> 7.1%; BIR: 10.1% <i>vs</i> 6.5%). Moreover, patients with FNMTC more frequently presented evidence of disease than patients with SDTC did. However, the disease-free survival of patients with FNMTC was not shorter than that of patients with SDTC (<i>P</i> ≥ 0.05).</p><h3>Conclusion</h3><p>Patients with FNMTC more often have aggressive characteristics at presentation and relatively worse clinical outcomes after RAI therapy. However, there was no statistically significant difference in the recurrence rate in the short-term follow-up. Considering that, FNMTC patients may be required more aggressive treatment approaches and closer postoperative monitoring.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 6","pages":"535 - 545"},"PeriodicalIF":2.5000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12149-025-02029-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
Compared with those of sporadic differentiated thyroid cancer (SDTC), the tumor characteristics of familial nonmedullary thyroid cancer (FNMTC) remain debatable. In addition, there is a paucity of data suggesting that their response to radioactive iodine (RAI) therapy differs from that of SDTC. We aimed to determine whether FNMTC is a homogenous biological entity that differs from SDTC in RAI therapy.
Methods
We retrospectively analyzed patients who underwent adjuvant ablative iodine radiotherapy between July 2016 and March 2020. We compared the differences in clinicopathological features and prognoses between the FNMTC and SDTC groups. The endpoint of the study was the rate of therapeutic response after 1 and 3 years of follow-up after first-line treatment. The response to therapy was classified into four categories: excellent response (ER), biochemical incomplete response (BIR), structural incomplete response (SIR) and indeterminate response (IDR). In addition, we conducted a meta-analysis of cohort studies to investigate the clinical outcomes.
Results
Of all the patients (n = 1758), 109 (6.2%) were classified as having FNMTC, whereas the remaining 1649 (93.8%) had SDTC. A greater proportion of FNMTC patients presented with extrathyroidal extension, capsular invasion, and multifocality (P = 0.01). In addition, patients with FNMTC were more likely to have advanced primary tumor stage and lymph node metastasis, but the differences were not statistically significant. At the end of follow-up (median follow-up of 3 years), the response to RAI therapy was significantly different between the two groups (ER: 66.1% vs 74.3%; IDR: 9.2% vs 12.1%; SIR: 14.7% vs 7.1%; BIR: 10.1% vs 6.5%). Moreover, patients with FNMTC more frequently presented evidence of disease than patients with SDTC did. However, the disease-free survival of patients with FNMTC was not shorter than that of patients with SDTC (P ≥ 0.05).
Conclusion
Patients with FNMTC more often have aggressive characteristics at presentation and relatively worse clinical outcomes after RAI therapy. However, there was no statistically significant difference in the recurrence rate in the short-term follow-up. Considering that, FNMTC patients may be required more aggressive treatment approaches and closer postoperative monitoring.
目的:与散发性分化型甲状腺癌(SDTC)相比,家族性非髓样甲状腺癌(FNMTC)的肿瘤特征尚存争议。此外,缺乏数据表明他们对放射性碘(RAI)治疗的反应与SDTC不同。我们的目的是确定FNMTC在RAI治疗中是否与SDTC不同的同质生物实体。方法:回顾性分析2016年7月至2020年3月期间接受辅助消融碘放疗的患者。我们比较了FNMTC组和SDTC组在临床病理特征和预后方面的差异。该研究的终点是一线治疗后随访1年和3年的治疗缓解率。治疗反应分为优异反应(ER)、生化不完全反应(BIR)、结构不完全反应(SIR)和不确定反应(IDR)四类。此外,我们对队列研究进行了荟萃分析,以调查临床结果。结果:1758例患者中,109例(6.2%)为FNMTC,其余1649例(93.8%)为SDTC。FNMTC患者更大比例表现为甲状腺外展、囊侵犯和多灶性(P = 0.01)。此外,FNMTC患者原发肿瘤分期晚期和淋巴结转移的可能性更大,但差异无统计学意义。在随访结束时(中位随访3年),两组患者对RAI治疗的反应有显著差异(ER: 66.1% vs 74.3%;印尼卢比:9.2% vs 12.1%;SIR: 14.7% vs 7.1%;BIR: 10.1% vs 6.5%)。此外,FNMTC患者比SDTC患者更频繁地出现疾病证据。但FNMTC患者的无病生存期并不短于SDTC患者(P≥0.05)。结论:FNMTC患者多表现为侵袭性,经RAI治疗后临床效果相对较差。但两组短期随访复发率差异无统计学意义。考虑到这一点,FNMTC患者可能需要更积极的治疗方法和更密切的术后监测。
期刊介绍:
Annals of Nuclear Medicine is an official journal of the Japanese Society of Nuclear Medicine. It develops the appropriate application of radioactive substances and stable nuclides in the field of medicine.
The journal promotes the exchange of ideas and information and research in nuclear medicine and includes the medical application of radionuclides and related subjects. It presents original articles, short communications, reviews and letters to the editor.